← All trials
NCT02971345
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2017
- Primary completion
- Jan 1, 2019
- Completion date
- Jun 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 253
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Fudan UniversityLead sponsor
- Jiangsu UniversityCollaborator
- Fudan UniversityOverall official - principal investigator
- Fudan UniversityStudy director
- Zhejiang UniversityCollaborator
- Changhai HospitalCollaborator
- Tengzhou Central People's HospitalCollaborator
- Harbin Medical UniversityCollaborator
- Central South UniversityCollaborator
- Lishui Country People's HospitalCollaborator
- Yancheng Third People's HospitalCollaborator
- Fujian Medical UniversityCollaborator
- LanZhou UniversityCollaborator
- Shanxi Medical UniversityCollaborator
- Soochow UniversityCollaborator
- Xiamen UniversityCollaborator
- Zhengzhou UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
- China Medical UniversityCollaborator
- Second People's Hospital of YibinCollaborator
- Anhui College of Traditional Chinese MedicineCollaborator
- Southern Medical UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.